Increased life expectancy along with an increasing share of elderly and senile patients in the structure of the population make the tasks of longer healthy life expectancy pressing. A set of activities aimed at optimization of management of patients within the framework of gerontological practice should include elimination and prevention of diagnostic and therapeutic errors. The basic risk factors of medical errors include high heterogeneity of elderly and senile patients, overburdened healthcare system, polypharmacy, including due to parallel prescription of drugs to the same patient by multiple medical professionals, concomitant diseases, and high comorbidity, measured by the Charlson Comorbidity Index. Mismanagement of elderly patients can result both from underestimated severity of the patient’s conditions, and from hyperdiagnostics. Typical errors of pharmacotherapy include use of potentially inappropriate medications, potential prescribing omissions, simultaneous prescription of drugs with high risk of clinically significant interactions, incorrect selection of dosage without taking into account the renal failure, which is associated with high risk of toxic effects. Affordability of medical aid for an elderly patient is another important social aspect influencing the patient’s quality of life. As far as basic ethical principles of management of elderly and senile patients go, it is necessary to respect independence, well-being and justice for the patients regarding possible obtaining of qualitative medical aid as compared with other age groups.
VIEWS 2209
A lack of the single criterion for classifying rare diseases as a group of orphan diseases is the main current problem. First, it is associated with rare detection of symptoms among patients, especially children. Second, specialists have a limited number of methods of detecting orphan diseases. As the disease is considered rare, it is not profitable for pharmaceutical companies to produce the preparations which are purchased not in large numbers, but in single packages, because expenses on clinical trials and marketing advertising exceed return of investment. The market of orphan drugs in Russia is at the stage of development and formation. Medical organizations that carry out medicinal therapy of patients with orphan diseases require a clear set of regulatory documents ensuring provision of medical and pharmaceutical aid. Special attention should be paid to drawing up the lists of medicinal preparations to treat the patients. Personified accounting of patients with detected orphan diseases is an important stage for medical and pharmaceutical organizations. Modern diagnostics of orphan diseases at early stages, especially in children, exploration of specialized genetic methods of research and making them accessible for the population constitute an essential problem.
VIEWS 1971
No properly formed and subsequent regulation concept has been presented until now by a number of the issues, which are essential for the pharmaceutical branch. Development and a complex structure of the state regional retail market of medicines, including the activity objects as part of organizations with various organizational and legal forms managed or coordinated by representatives of public entities, have been reviewed in complex within the trial. The model of the structure of the state segment considering organizational and legal interactions used during examination of the regional pharmaceutical market in the Kostroma region has been suggested. Distribution of objects within the state segment structure was analyzed. The differences in the strategies of functioning and development of the state and private segments of the regional retail market of medicines have been identified. Legal preconditions and social and economic conditions of the growing role of healthcare institutions in the system of drug supply of population have been designated. It has been established that the tendencies intensifying participation of the state in the system of drug supply to ensure proper management of budgetary resources and risk prevention were accompanied by previously adopted extra-branch changes of legislation. This could result in reduction of the state segment in economics that would inevitably lead to serious changes in the structure of the pharmaceutical market and redistribution of social load among its participants [2]. A serious understanding of prospects of functioning of the state segment of retail trade of medicines is required both at the level of regulatory agencies and within the professional community considering the preservation of social services of medicinal aid and decreased risks of negative phenomena on the pharmaceutical market.
VIEWS 1857